›› 2009, Vol. 29 ›› Issue (9): 1035-.

• Original article (Basic research) • Previous Articles     Next Articles

Resistance reverse effects of honokiol on multidrug resistance of U937/ADR cell line

XUE Fang1, CHENG Zhi-yong2, LIANG Wen-tong2, CHEN Hao1, WANG Su-yun1, YAO Li1, PAN Ling1   

  1. 1. Department of Hematology, Key Laboratory of Hematology of Hebei Province, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China；2. Department of Hematology and Oncology, the First Hospital of Baoding, Baoding 071000, China
  • Online:2009-09-25 Published:2009-09-29
  • Supported by:

    Program of Scientific Problem Tackling of Hebei Province, 072761130

PDF (PC)

1462

Abstract:

Objective To investigate reverse effects of honokiol (HNK) on human multidrug resistance of in vitro leukemia U937/ADR cell line. Methods According to high-dose (IC50) short-term adriamycin induction method, human acute myeloid leukemia (AML) multidrug resistant U937/ADR cell line was produced. The drug resistances to different chemotherapeutic drugs were measured. Low-dose (IC20) HNK and different chemotherapeutic drugs were used to U937/ADR for measuring the drug resistance reversal fold. Drug excretion was tested by rhodamine 123 (Rho123). NF-κB (p65) and MDR1(P-gp) were detected by real-time fluorescent relativequantification reverse transcriptional PCR (FQ-PCR) or Western blotting after U937/ADR treated with different concentrations of HNK. NF-κB activity was also detected by NF-κB activity detection kits. Results Multidrug resistance U937/ADR cell line was successfully established and the ADR resistant index was 11 fold than U937 cells. Low concentration of HNK combination with adriamycin could reverse drug resistance and reversal index of ADR was 2.2 fold after treated with 6.5 μg/mL HNK. It also could decrease the NF-κB (p65) and MDR1(P-gp) expressions dose-dependently. Conclusion HNK could inhibit NF-κB activity to inhibit P-gp expression and reverse the multidrug resistance of U937/ADR cells.

Key words: honokiol, multidrug resistance, U937/ADR cell line, NF-κB, P-gp

CLC Number: